Article
Microwave ablation with continued EGFR tyrosine kinase inhibitor therapy prolongs disease control in non-small-cell lung cancers with acquired resistance to EGFR tyrosine kinase inhibitors.
Thoracic cancer - 1 Aug 2018
Li Xin, Qi Han, Qing Gou, Song Ze, Xie Lin, Cao Fei, Chen Xiaoming, Fan Weijun
Abstract excerpt
BACKGROUND: Although patients with EGFR-mutant non-small-cell lung cancer (NSCLC) benefit from treatment with EGFR-tyrosine kinase inhibitors (TKIs), outcomes are limited by the eventual development of acquired resistance. We conducted a retrospective study to evaluate the efficacy and feasibility of EGFR-TKI therapy beyond focal progression, associated with microwave ablation. METHODS: Patients with metastatic...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.